Sage Journals: Discover world-class research

Abstract

Although the adult human brain has a small number of neural stem cells, they are insufficient to repair the damaged brain to achieve significant functional recovery for neurodegenerative diseases and stroke. Stem cell therapy, by either enhancing endogenous neurogenesis, or transplanting stem cells, has been regarded as a promising solution. However, the harsh environment of the diseased brain posts a severe threat to the survival and correct differentiation of those new stem cells. Hormesis (or preconditioning, stress adaptation) is an adaptation mechanism by which cells or organisms are potentiated to survive an otherwise lethal condition, such as the harsh oxidative stress in the stroke brain. Stem cells treated by low levels of chemical, physical, or pharmacological stimuli have been shown to survive better in the neurodegenerative brain. Thus combining hormesis and stem cell therapy might improve the outcome for treatment of these diseases. In addition, since the cell death patterns and their underlying molecular mechanism may vary in different neurodegenerative diseases, even in different progression stages of the same disease, it is essential to design a suitable and optimum hormetic strategy that is tailored to the individual patient.

Keywords

hormesis preconditioning regenerative medicine stem cells cell death apoptosis necrosis autophagy molecular chaperone Hsp90 inhibitors

INTRODUCTION

Regenerative medicine is an emerging field of treatments based on the concept of producing new cells to replace malfunctioning or damaged ones as a vehicle to treat disease and injury (Steindler 2007; Hess and Borlongan 2008). It could aid in easing symptoms or even reverse disease progression of diseases where pharmacological interventions and other treatment modalities are no longer sufficient or not available (Gogel et al. 2011). This is especially true for diseases associated with aging such as neurodegenerative diseases, type II diabetes, and heart failure (Haas et al. 2005; Chang et al. 2007; Caspi et al. 2007). This is also true for medical conditions resulting from damage to cells due to acute disease, such as trauma, infarction and burns (Li et al. 2008a; Chang et al. 2007).

Although stem or progenitor cells are presumed to survive various stresses, the harsh insults from the diseased proteins, inflammatory cytokines, and cytotoxic cells in the areas of tissue damage and regeneration may significantly hamper their viability, especially during the first few days after transplantation (Norgaard et al. 2006; Bliss et al. 2006; Kelly et al. 2004; Hicks et al. 2009).

A term initially used in toxicology, hormesis has been defined as a dose-response relationship in which there is an inhibitory response at higher doses but a stimulatory response at lower doses, resulting in a U-shaped or inverted U-shaped dose response (Fig. 1) (Mattson 2008; Calabrese et al. 2007; Kendig et al. 2010). When given at a small quantity, a harmful substance gives rise to beneficial effects in living organisms. A good examples is alcohol consumption, in which light drinking helps prevent heart disease and stroke (Cook and Calabrese 2006). Other examples of hormesis include physical exercise, ischemia preconditioning, and chemical treatment of cells (Calabrese et al. 2007; Mattson 2008; Calabrese et al. 2008a; Wang et al. 2012; Wang et al. 2011).

FIGURE 1.

The U-shaped dose response curve of Hormesis. From Calabrese and Baldwin (Calabrese and Baldwin 2001), used with permission.

Hormesis is believed to be a common paradigm throughout nature and is the foundation of evolution (Calabrese et al. 2007; Norgaard et al. 2006; Rattan 2004; Mattson 2008). Over the years, life on earth has went through harsh environment in which cells and organisms were often exposed to adverse stresses, including free radicals and toxic substances. Only those organisms that developed a complex mechanism to adapt to or cope with the changing environment have survived (Mattson 2008). Several studies have reported that a mild stress produces stress adaptation in cells that potentiates them to endure a much severe condition (reduction of cell death) (Norgaard et al. 2006; Geraci et al. 2006; Kraft et al. 2006; Madhavan et al. 2006; Mattson 2008; Kendig et al. 2010; Wang et al. 2011).

In this article, we will discuss the potential application of hormesis in regenerative medicine for neurodegenerative diseases and stroke. Since cell death/survival is crucial for regenerative medicine, and the cell death patterns and their underlying molecular mechanism may vary in different neurodegenerative diseases, even in different progression stages of the same disease, it is essential to design a suitable and optimum hormetic strategy that is tailored to the individual patient, we will first briefly review the common cell death pathways related to neural stem/progenitor cells, namely apoptosis, autophagy, and necrosis, which could be potentially averted by hormesis.

CELL DEATH PATHWAYS

Apoptosis - the programmed cell death

Apoptosis is an important part of life for multicellular organisms (see reviews (Lockshin and Zakeri 2004; Jin and El-Deiry 2005; Rufini and Melino 2011)). It plays an essential role in development and homeostasis. During early development of many organs, for example the brain and the fingers, cells are produced in excess which eventually undergo apoptosis and thereby contribute to organ and tissue morphogenesis. Features of apoptosis include condensed nuclei, cell shrinkage, cell membrane blebbing, and DNA fragmentation. Apoptotic cell death is considered to be a major cell death pathway for transplanted stem cells, including neural progenitor cells (NPCs), mesenchymal stem cells (MSCs), and bone marrow stem cells (BMSCs) (Theus et al. 2008; Wang et al. 2011; Geng 2003). For example, It has been reported that only less than 1% of the injected BMSCs survive past one week (Toma et al. 2002).

Apoptotic cell death is usually categorized into two distinct pathways: caspase-dependent and caspase-independent (Jin and El-Deiry 2005; Rufini and Melino 2011; Lockshin and Zakeri 2004) (Fig. 2). In the caspase-dependent pathway, a series of specific cysteine proteases, named caspases, are activated in a cascade of proteolytic maturation steps in response to environmental or physiological cell death signals (Fig. 3) (Kroemer et al. 2009; Galluzzi et al. 2012). The initiator caspases, caspase 8 and caspase 9, are derived from procaspase 8 and procaspase 9, which will activate the effector caspases, such as caspase 3, and caspase 7 (Sivananthan et al. 2010). The activated effector caspases then cleave a subset of more than 100 cellular proteins which are important for cell structure, cellular repair, and cell cycle related proteins (Degterev et al. 2003), causing arrest of vital cellular functions as well as lethal catabolic reactions (Martins et al. 2011; Cheng et al. 2010; Tadokoro et al. 2010; Boatright et al. 2003). In mammals, the caspase-dependent apoptosis is further subcategorized into extrinsic pathway (death receptor pathway) and intrinsic pathway (mitochondria pathway) depending upon the source of the stress signals (Fig. 3). The extrinsic pathway is activated by extrinsic stimuli such as binding of ligands to cell surface death receptors, which include Fas, tumor necrosis factor receptor, and Trail receptors. On the other hand, the intrinsic pathway is initiated by diverse cellular apoptotic stimuli, such as DNA damage and virus infection, which converge at the mitochondria (Baliga and Kumar 2003). Release of cytochrome c from the mitochondria to the cytoplasm activates the caspase cascade. Cytosolic cytochrome c (cytoC) associates with apoptosis protease- activating-factor 1 (Apaf-1) and procaspase 9, generating an intracellular cell death inducing-complex known as “apoptosome”. Within the apoptosome, caspase 9 is activated, leading to the cleavage of procaspase 3 to form the activated caspase 3. The extrinsic and intrinsic pathway then converge on the caspase 3 and subsequently on other proteases and nucleases that drive the cleavage of chromosome DNA and other terminal events of apoptosis (Baliga and Kumar 2003; Kroemer et al. 2007). However, caspase inhibition rarely prevents apoptosis completely, indicating that there are caspase-independent pathways (Kroemer et al. 2007; Galluzzi et al. 2012; Mailleux et al. 2007; Cordeiro et al. 2010; Vandenabeele et al. 2010; Broker et al. 2005). Apoptosis inducing factor (AIF) and cofilin operate as death-effectors in the complete absence of caspase activation (Fig. 2) (Patterson et al. 2000; Wabnitz et al. 2010; Lee et al. 2010). The key regulators of caspase-independent apoptosis are located on the mitochondria membranes, whose integrity (mitochondrial outer membrane permeabilization (MOMP)) is regulated by multiple proteins and processes, including Bcl-2 family members (Esposti 2010), BH3-only proteins (Cabon et al. 2012), tumor suppressor protein P53 (Galluzzi et al. 2008a; Galluzzi et al. 2011), Protein kinase Cs (Allen-Petersen et al. 2010; Paoletti et al. 2010), epigenetic perturbations (Yelamanchili et al. 2010; Tenedini et al. 2010; Sancho-Pelluz et al. 2010; Lei et al. 2010; Lanzillotta et al. 2010), and cell cycle perturbations (Fig. 2) (Mitchell et al. 2010).

FIGURE 2.

Schematic presentation of the caspase dependent and independent apoptotic pathway.

FIGURE 3.

Schematic presentation of the intrinsic and extrinsic pathways of the caspase dependent apoptotic pathways.

Autophagy - A physiological hormesis case

The autophagic cell death is initially considered a “Type II” cell death pathway in that it requires activation of the lysosomal compartment, in which parts of the cytoplasm are enwrapped in double-memberaned vesicles (called autophagosomes) and degraded by lysosome hydrolases (Lockshin and Zakeri 2004; Madeo et al. 2010; Criollo et al. 2010). Autophagy is a normal physiological process that functions to turn over abnormal proteins and organelles (Lockshin and Zakeri 2004) and is closely related to apoptosis (Martins et al. 2011; Galluzzi et al. 2008b; Rufini and Melino 2011; Agostini et al. 2011). Autophagy can counteract or sustain apoptosis or vise versa and exhibit a typical hormesis phenotype. Low levels of autophagy is pro-survival, as it allows for the removal of the damaged proteins and helps maintain metabolic homeostasis (Eisenberg-Lerner et al. 2009). Conversely, a high level of autophagy leads to cell death and cooperates with apoptosis because of the extensive cellular damage (Galluzzi et al. 2008b; Eisenberg-Lerner et al. 2009). Autophagy and apoptosis exhibit cross talk on the molecular level, too. For example, the apoptosis-inducing BH3 proteins have been shown to liberate Beclin 1 from its interaction with Bcl-2-like proteins, thereby leading to autophagy (Buttner et al. 2011; Juhasova et al. 2011).

Necrosis -

Necrosis is historically considered a “type III” cell death pathway (Golstein and Kroemer 2007; Kroemer et al. 2009; Krysko et al. 2008a). It is originally defined as a type of cell death that lacks the features of apoptosis and autophagy (Golstein and Kroemer 2007; Syntichaki and Tavernarakis 2002; Nicotera and Melino 2004; Chiong et al. 2011). Cells suffer necrotic cell death when exposed to extreme environmental or physiological conditions (Syntichaki and Tavernarakis 2002). Necrosis was often considered chaotic and uncontrolled, leading to local inflammation, and being connected to unwanted cell loss in many types of human pathologies (Golstein and Kroemer 2007; Festjens et al. 2006; Yuan 2006). However, recent advances have slowly overturned this grim prospect and suggested that the occurrence and course of necrosis might be tightly regulated (Syntichaki and Tavernarakis 2002; Golstein and Kroemer 2007; Nicotera and Melino 2004). Increasing evidence demonstrates that regulated necrosis, referred to as necroptosis (Vanlangenakker et al. 2012; Nicotera and Melino 2004), is not anymore an isolated observation of a particular cell line or in certain conditions, but is also recognized as an in vivo cellular defense mechanism against viral infections and as being critically involved in ischemia-reperfusion damage(Degterev et al. 2005; Galluzzi et al. 2012; Vanlangenakker et al. 2012). Breakthroughs come from the discovery that the kinase activities of RIPK1/ RIPK3 are crucial for necroptosis (Degterev et al. 2008; He et al. 2009; Zhang et al. 2009; Vandenabeele et al. 2010). Despite these advances, there are still no specific positive biochemical biomarkers for the in situ detection of necrosis in vitro and in vivo (Vanlangenakker et al. 2012). The release of intracellular proteins such as high-mobility group box 1 protein (HMGB1) (Scaffidi et al. 2002) and cyclophilin A (CypA) (Christofferson and Yuan 2010) has been proposed as a candidate necrotic biomarker. However, HMGB1 and CypA can also be passively released from cells dying by secondary necrosis following apoptosis (Scaffidi et al. 2002) or actively secreted from activated immune cells or cells dying from pyroptosis, a term introduced to describe necrosis-like cell death that is dependent on caspase-1 activity (Fink and Cookson 2005). The ratio between caspase-cleaved cytokeratin-18 released from apoptotic cells and intact cytokeratin-18 released from cells dying from other causes, including necrosis, has also been proposed as a marker to determine qualitatively and quantitatively the extent of both types of cell death (Kramer et al. 2004), but should again be taken with caution (Vanlangenakker et al. 2012). So far, the mostly used method to determine necrosis is to combine morphology with immunofluorescence studies (Vanlangenakker et al. 2012; Krysko et al. 2008a; Krysko et al. 2008b). Necrotic cells typically exhibit intact extracellular nuclei in electron microscopy images, and are Tdt-mediated dUTP nick end labeling (TUNEL) positive, but caspase 3 negative in immunofluorescence images (Krysko et al. 2008a; Krysko et al. 2008b; Vanlangenakker et al. 2012; Golstein and Kroemer 2007; Kroemer et al. 2009).

MECHANISMS OF HORMESIS IN NEURAL CELLS

Hormesis stimulates multiple bioprotective mechanism, including induction of cytoprotective pathways (such as molecular chaperones), antioxidative stress, DNA repair, and immune system activation to protect neural cells from various forms of cell death (Calabrese et al. 2008a; Calabrese et al. 2008b; Kendig et al. 2010). Here, we will briefly discuss the induction of anti-apoptotic molecular chaperones and antioxidative stress proteins by hormesis.

Expression of molecular chaperones (usually called heat shock proteins (Hsps)) is an important intracellular defense mechanism against stressful conditions (Homma et al. 2007; Wang et al. 2001, 2003, 2004). Hsps are indispensible for protein homeostasis in normal physiological conditions (Calabrese et al. 2010; Terasawa et al. 2005; Whitesell and Lindquist 2005; Trepel et al. 2010). They also serve a vital role of protein protection and cell protection against cell death during adverse situations (Arumugam et al. 2006). The importance of Hsps in protection of neural cells against neurodegenerative diseases is increasingly recognized. It has been found that levels of Hsp70 and GRP78 are increased in neurons subjected to low level stressors, which serve to protect the neurons against otherwise lethal levels of oxidative or metabolic stresses (Guo et al. 2001; Arumugam et al. 2006).

Low level of free radicals generated by mild oxidative stresses can activate signaling pathways that increase resistance of neurons to more severe stresses (Otani 2004; Juhaszova et al. 2004). This hormesis mechanism involves activation of the N-Methyl-D-Aspartate (NMDA) receptor and brain- derived nerve factor (BDNF) (Marini and Novelli 1991; Marini et al. 2008; Arumugam et al. 2006). Multiple antioxidative systems are triggered or enhanced in response to mild oxidative stresses, including antioxidative enzymes, glutathione and proteins involved in stabilization of mitochondrial membranes (Liu et al. 2002; Arthur et al. 2004).

STEM CELL THERAPY OF NEURODEGENERATIVE DISEASES AND STROKE

Chronic neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease create a considerable burden to individuals, families, and the society. In addition, the catastrophic impact of stroke to quality of life is severe. Thus, it is of pivotal importance to develop innovative methods to treat or prevent these diseases. Regenerative medicine has emerged to be one of the most promising approaches.

Two sets of strategies have been proposed to regenerate cells in order to repair the damaged brain tissues. The first strategy is through donor cell transplantation (from either autologous or allogenic cell sources). Over the last decade, credible data have demonstrated the safety and feasibility of injected stem cells in inducing neural cell regeneration and functional recovery in animal models of stroke, Parkinson's disease, Huntington's disease, and Alzheimer's disease (Gogel et al. 2011; Francis and Wei 2010; Haider and Ashraf 2010; Herrmann et al. 2010; Savitz et al. 2011). Human neural stem cells (HNSCs) transplanted into aged rat brains differentiated into neural cells and significantly improved the cognitive functions of the animals (Sugaya 2005; Sugaya et al. 2006; Roitberg et al. 2006; Qu et al. 2001; Winkler 2001). Cells from different sources have been examined and proved effective, including neural stem cells (NSC) derived from embryonic stem (ES) cells or induced pluripotent stem (iPS) cells, and fetal or adult neural stem cells (Zeng et al. 2010; Gogel et al. 2011; Haider and Ashraf 2010; Wang et al. 2011; Haas et al. 2005; Wang et al. 2009; Theus et al. 2008; Wei et al. 2012; Kelly et al. 2004; Bliss et al. 2006; Horie et al. 2011). Pluripotent stem cells are no longer seen as a safe cell sources as its transplantation leads to teratoma formation (Gogel et al. 2011). Therefore, direct differentiation and purification of ESCs into defined neural subtypes is preferred.

Another cell source for transplantation is MSCs (Haider and Ashraf 2010; Wang et al. 2009; Wei et al. 2012; Geng 2003; Toma et al. 2002). MSCs can be derived from a variety of tissues such as bone marrow and cord blood. As they seem to penetrate the blood brain barrier, no invasive intracerebral surgery is required and instead a peripheral infusion can be performed to deliver these cells to the brain. However, questions still remain that how many of these cells travel to the brain and to what extent they differentiate into different neural cell types (Gogel et al. 2011).

The second strategy is to enhance endogenous neurogenesis and thus boost endogenous repair mechanisms of the brain (Savitz et al. 2011). Much evidence has been found that the brain is capable of regenerating neurons after their maturation (Sugaya 2005; Sugaya et al. 2006; Qu et al. 2001; Eriksson et al. 1998; Allen et al. 2001; Aimone et al. 2006; Jagasia et al. 2006), and stroke can stimulate neurogenesis migration of neural stem/progenitor cells into damaged brain region (Greenberg 2007; Wiltrout et al. 2007; Chopp et al. 2007; Liu et al. 2007). But the extent to which this neurogenesis can replace lost neural cells and contribute to functional improvement is not clear (Gogel et al. 2011). It is believed that protection, and/or enhancement of proliferation, of the endogenously-newly-generated neural cells by mechanisms of hormesis could be a viable approach, by which a sufficient amount of cells generated to promote the functional recovery of the patients (Gogel et al. 2011; Hess and Borlongan 2008; Marini et al. 2008).

HORMESIS FOR REGENERATIVE MEDICINE

Hormesis has been proven to reduce cell death and aid in survival in both of these two scenarios. For the strategy to transplant donor stem cells, the following hormetic methods have been found to enhance stem cell survival and/or mobilization: mild hypoxia (Lian and Tse 2010; Kamota et al. 2009; Wei et al. 2012; Theus et al. 2008), the antibiotic minocycline (Sakata et al. 2012), an endogenous peptide apelin (Zeng et al. 2012; Wang et al. 2012), and others (Wisel et al. 2009; Salloum et al. 2012; Hoke et al. 2012; Kwon et al. 2008). Our group has found that treatment with a low dose Hsp90 inhibitor 17-N-Allylamino-17-demethoxygel-danamycin (17-AAG) protects NPCs from naturally-occurring and stress induced apoptosis, with a typical reversed U-shaped hormetic dose-response relationship (Wang et al. 2011) (Fig. 4). Mechanistically, low dose 17-AAG activates the stress response pathway, MAP kinase pathway, and PI3K/Akt pathways. This is of profound clinical relevance, since many Hsp90 inhibitors, including 17-AAG, are in clinical trials against multiple malignancies, and have overcome the toxicity and solubility problems (Kummar et al. 2010; Trepel et al. 2010; Waza et al. 2005, 2006).

FIGURE 4.

The Hsp90 inhibitor 17-AAG induces an inverted Ushaped cell survival/death dose-response curve in NPCs (Wang et al. 2011).

Hormesis is also a promising strategy to protect endogenous neurons and enhance endogenous neurogenesis (Gogel et al. 2011; Marini et al. 2008). One example of hormetic protection of neurons is glutamate, the major excitatory amino acid that mediates physiological excitation. Glutamate is involved in both acute and chronic neurodegenerative disorders (Dobrek and Thor 2011; Lau and Tymianski 2010). High level activation of the ionotrophic glutamate receptor leads to neuronal cell death. However, low level activation of glutamate receptors exerts neuron protection (Marini et al. 2008; Marini and Novelli 1991; Jonas et al. 2001; Calabrese et al. 2007). Another interesting proposal is to utilize the cytoprotective effect of autophagy to protect neurons from the hostile disease environment. Since mild autophagy can lead to the removal of damaged and potentially dangerous mitochondria, it increases the threshold for cell death induction by MOMP-inducing agents or stressors (Blagosklonny 2010; Bennett et al. 2010; Deng et al. 2010; Degli Esposti et al. 2011). Thus mild autophagy may be a promising strategy to reduce the propensity of neurons to undergo apoptosis or necrosis (Martins et al. 2011).

We have mentioned that chronic or acute brain damage induces neurogenesis, although their beneficial effect is not clear. Supporting these newly generated cells by infusion of neurotrophic factors or other measures that enhance neurogenesis, or boost the survival of the newly generated stem/progenitor cells, could help rebuild a sufficient amount of the lost circuitry, hence improving functional recovery of the patients (Gogel et al. 2011; Hess and Borlongan 2008; Li et al. 2008b; Misumi et al. 2008). Many types of stimulation methods have been tested and proven beneficial, including ischemia preconditioning, exercise, and peripheral stimulation (Li et al. 2008b; Andoh et al. 2002; Dawson 2002). Our group found that injection of 17-AAG increased the number of newly generated neural cells, in both the subventricular zone and the subgranular zone, by about 60%, accompanied by triggering phosphorylation of cytoprotective kinases Akt and GSK-3b in the brain (Wang et al. 2011).

CONCLUSIONS AND PERSPECTIVES

Stem cells delivered into the brain (or newly regenerated) can support a certain amount of neural function by secreting trophic factor vascular endothelial growth factor (Bliss et al. 2006; Horie et al. 2011) However, the injected cells do not infiltrate and survive the damaged region, let alone reconstruction of the lost neural circuit, undermining the idea and full potential of regenerative medicine (Bliss et al. 2006; Kelly et al. 2004; Horie et al. 2011). Therefore it is vital to optimize the treatment procedure so that the newly generated (or transplanted) cells survive and correctly differentiate into desired cell types in the brain. Many studies have found that hormesis potentiates stem cells to a state in which they can endure much harsher environment and improve functional recovery in animal models of neurodegenerative disease. Hence it is rational to promote the combination of stem cell therapy with hormesis to achieve a more desirable outcome, and encouraging more research in the related field.

Cell death is a very complex process and our understanding of its mechanism is advancing in an unprecedented pace. More importantly, since the cell death patterns and their underlying molecular mechanism may vary in different diseases and even in different progression stages of the same disease, it is essential to design a suitable and optimum hormetic strategy that is tailored to the individual patient. Thus it calls for comprehensive approaches to achieve protection of the newly generated (or transplanted) cells so that they are more suited for regenerative medicine.

Footnotes

ACKNOWLEDGEMENT

This work is supported by a grant from American Heart Association and an intramural grant from Georgia Health Sciences University to GW. I am thankful to Dr Erhard Bieberich for critical reading and valuable suggestions. I am also thankful for the support by the Institute of Molecular Medicine of Genetics (under the directorship of Dr. Lin Mei).

References

Agostini

Tucci

and Melino

. 2011. Cell death pathology: perspective for human diseases. Biochem Biophys Res Commun, 414, 451–5.

Aimone

Wiles

and Gage

. 2006. Potential role for adult neurogenesis in the encoding of time in new memories. Nat Neurosci, 9, 723–7.

Allen-Petersen

Miller

Neville

Anderson

Nakayama

and Reyland

. 2010. Loss of protein kinase C delta alters mammary gland development and apoptosis. Cell Death Dis, 1, e17.

Allen

van Praag

Ray

Weaver

Winrow

Carter

Braquet

Harrington

Ried

Brown

Gage

and Barlow

. 2001. Ataxia telangiectasia mutated is essential during adult neurogenesis. Genes Dev, 15, 554–66.

Andoh

Chock

and Chiueh

. 2002. Preconditioning-mediated neuroprotection: role of nitric oxide, cGMP, and new protein expression. Ann N Y Acad Sci, 962, 1–7.

Arthur

Lim

Meloni

Munns

Chan

and Knuckey

. 2004. The protective effect of hypoxic preconditioning on cortical neuronal cultures is associated with increases in the activity of several antioxidant enzymes. Brain Res, 1017, 146–54.

Arumugam

Gleichmann

Tang

and Mattson

. 2006. Hormesis/preconditioning mechanisms, the nervous system and aging. Ageing Res Rev, 5, 165–78.

Baliga

and Kumar

. 2003. Apaf-1/cytochrome c apoptosome: an essential initiator of caspase activation or just a sideshow? Cell Death Differ, 10, 16–8.

Bennett

Fleming

O'Prey

Ryan

and Leung

. 2010. Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death Dis, 1, e72.

10.

Blagosklonny

. 2010. Linking calorie restriction to longevity through sirtuins and autophagy: any role for TOR. Cell Death Dis, 1, e12.

11.

Bliss

Kelly

Shah

Foo

Kohli

Stokes

Sun

Masel

Kleppner

Schallert

Palmer

and Steinberg

. 2006. Transplantation of hNT neurons into the ischemic cortex: cell survival and effect on sensorimotor behavior. J Neurosci Res, 83, 1004–14.

12.

Boatright

Renatus

Scott

Sperandio

Shin

Pedersen

Ricci

Edris

Sutherlin

Green

and Salvesen

. 2003. A unified model for apical caspase activation. Mol Cell, 11, 529–41.

13.

Broker

Kruyt

and Giaccone

. 2005. Cell death independent of caspases: a review. Clin Cancer Res, 11, 3155–62.

14.

Buttner

Ruli

Vogtle

Galluzzi

Moitzi

Eisenberg

Kepp

Habernig

Carmona-Gutierrez

Rockenfeller

Laun

Breitenbach

Khoury

Frohlich

Rechberger

Meisinger

Kroemer

and Madeo

. 2011. A yeast BH3-only protein mediates the mitochondrial pathway of apoptosis. EMBO J, 30, 2779–92.

15.

Cabon

Galan-Malo

Bouharrour

Delavallee

Brunelle-Navas

Lorenzo

Gross

and Susin

. 2012. BID regulates AIF-mediated caspase-independent necroptosis by promoting BAX activation. Cell Death Differ, 19, 245–56.

16.

Calabrese

Bachmann

Bailer

Bolger

Borak

Cai

Cedergreen

Cherian

Chiueh

Clarkson

Cook

Diamond

Doolittle

Dorato

Duke

Feinendegen

Gardner

Hart

Hastings

Hayes

Hoffmann

Ives

Jaworowski

Johnson

Jonas

Kaminski

Keller

Klaunig

Knudsen

Kozumbo

Lettieri

Liu

Maisseu

Maynard

Masoro

McClellan

Mehendale

Mothersill

Newlin

Nigg

Oehme

Phalen

Philbert

Rattan

Riviere

Rodricks

Sapolsky

Scott

Seymour

Sinclair

Smith-Sonneborn

Snow

Spear

Stevenson

Thomas

Tubiana

Williams

and Mattson

. 2007. Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Toxicol Appl Pharmacol.

17.

Calabrese

and Baldwin

. 2001. U-shaped dose-responses in biology, toxicology, and public health. Annu Rev Public Health, 22, 15–33.

18.

Calabrese

Bates

Mancuso

Cornelius

Ventimiglia

Cambria

Di Renzo

De Lorenzo

and Dinkova-Kostova

. 2008a. Curcumin and the cellular stress response in free radical-related diseases. Mol Nutr Food Res, 52, 1062–73.

19.

Calabrese

Cornelius

Dinkova-Kostova

Calabrese

and Mattson

. 2010. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal, 13, 1763–811.

20.

Calabrese

Cornelius

Mancuso

Pennisi

Calafato

Bellia

Bates

Giuffrida Stella

Schapira

Dinkova Kostova

and Rizzarelli

. 2008b. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem Res, 33, 2444–71.

21.

Chang

Shyu

Lin

and Li

. 2007. Regenerative therapy for stroke. Cell Transplant, 16, 171–81.

22.

Cheng

Betin

Weir

Shelmani

Moss

and Lane

. 2010. Caspase cleavage of the Golgi stacking factor GRASP65 is required for Fas/CD95-mediated apoptosis. Cell Death Dis, 1, e82.

23.

Chiong

Wang

Pedrozo

Cao

Troncoso

Ibacache

Criollo

Nemchenko

Hill

and Lavandero

. 2011. Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis, 2, e244.

24.

Chopp

Zhang

and Jiang

. 2007. Neurogenesis, angiogenesis, and MRI indices of functional recovery from stroke. Stroke, 38, 827–31.

25.

Christofferson

and Yuan

2010. Cyclophilin A release as a biomarker of necrotic cell death. Cell Death Differ, 17, 1942–3.

26.

Cook

and Calabrese

2006. The importance of hormesis to public health. Environ Health Perspect, 114, 1631–5.

27.

Cordeiro

Guo

Coxon

Duggan

Nizari

Normando

Sensi

Sillito

Fitzke

Salt

and Moss

. 2010. Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo. Cell Death Dis, 1, e3.

28.

Criollo

Senovilla

Authier

Maiuri

Morselli

Vitale

Kepp

Tasdemir

Galluzzi

Shen

Tailler

Delahaye

Tesniere

De Stefano

Younes

Harper

Pierron

Lavandero

Zitvogel

Israel

Baud

and Kroemer

. 2010. The IKK complex contributes to the induction of autophagy. EMBO J, 29, 619–31.

29.

Dawson

. 2002. Preconditioning-mediated neuroprotection through erythropoietin? Lancet, 359, 96–7.

30.

Esposti

D Degli

Sebagh

Pham

Reffas

Pous

Brenner

Azoulay

and Lemoine

. 2011. Ischemic preconditioning induces autophagy and limits necrosis in human recipients of fatty liver grafts, decreasing the incidence of rejection episodes. Cell Death Dis, 2, e111.

31.

Degterev

Boyce

and Yuan

. 2003. A decade of caspases. Oncogene, 22, 8543–67.

32.

Degterev

Hitomi

Germscheid

Ch'en

Korkina

Teng

Abbott

Cuny

Yuan

Wagner

Hedrick

Gerber

Lugovskoy

and Yuan

. 2008. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol, 4, 313–21.

33.

Degterev

Huang

Boyce

Jagtap

Mizushima

Cuny

Mitchison

Moskowitz

and Yuan

. 2005. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol, 1, 112–9.

34.

Deng

Feng

and Broaddus

. 2010. The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress. Cell Death Dis, 1, e32.

35.

Dobrek

and Thor

. 2011. Glutamate NMDA receptors in pathophysiology and pharmacotherapy of selected nervous system diseases. Postepy Hig Med Dosw (Online), 65, 338–46.

36.

Eisenberg-Lerner

Bialik

Simon

and Kimchi

. 2009. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ, 16, 966–75.

37.

Eriksson

Perfilieva

Bjork-Eriksson

Alborn

Nordborg

Peterson

and Gage

. 1998. Neurogenesis in the adult human hippocampus. Nat Med, 4, 1313–7.

38.

Esposti

. 2010. Bcl-2 antagonists and cancer: from the clinic, back to the bench. Cell Death Dis, 1, e37.

39.

Festjens

Berghe

T Vanden

and Vandenabeele

. 2006. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta, 1757, 1371–87.

40.

Fink

and Cookson

. 2005. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun, 73, 1907–16.

41.

Francis

and Wei

. 2010. Human embryonic stem cell neural differentiation and enhanced cell survival promoted by hypoxic preconditioning. Cell Death Dis, 1, e22.

42.

Galluzzi

Morselli

Kepp

Tajeddine

and Kroemer

. 2008a. Targeting p53 to mitochondria for cancer therapy. Cell Cycle, 7, 1949–55.

43.

Galluzzi

Morselli

Kepp

Vitale

Pinti

and Kroemer

. 2011. Mitochondrial liaisons of p53. Antioxid Redox Signal, 15, 1691–714.

44.

Galluzzi

Morselli

Vicencio

Kepp

Joza

Tajeddine

and Kroemer

. 2008b. Life, death and burial: multifaceted impact of autophagy. Biochem Soc Trans, 36, 786–90.

45.

Galluzzi

Vitale

Abrams

Alnemri

Baehrecke

Blagosklonny

Dawson

El-Deiry

Fulda

Gottlieb

Green

Hengartner

Kepp

Knight

Kumar

Lipton

Madeo

Malorni

Mehlen

Nunez

Peter

Piacentini

Rubinsztein

Shi

Simon

Vandenabeele

White

Yuan

Zhivotovsky

Melino

and Kroemer

2012. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death. 2012. Cell Death Differ, 19, 107–20.

46.

Geng

. 2003. Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerotic coronary disease and ischemic heart failure. Ann N Y Acad Sci, 1010, 687–97.

47.

Geraci

Turturici

Galli

Cossu

Giudice

and Sconzo

. 2006. Stress response in mesoan-gioblast stem cells. Cell Death Differ, 13, 1057–63.

48.

Gogel

Gubernator

and Minger

. 2011. Progress and prospects: stem cells and neurological diseases. Gene Ther, 18, 1–6.

49.

Golstein

and Kroemer

. 2007. Cell death by necrosis: towards a molecular definition. Trends Biochem Sci, 32, 37–43.

50.

Greenberg

. 2007. Neurogenesis and stroke. CNS Neurol Disord Drug Targets, 6, 321–5.

51.

Guo

Lee

Lane

and Mattson

. 2001. Iodoacetate protects hippocampal neurons against excitotoxic and oxidative injury: involvement of heat-shock proteins and Bcl-2. J Neurochem, 79, 361–70.

52.

Haas

Weidner

and Winkler

. 2005. Adult stem cell therapy in stroke. Curr Opin Neurol, 18, 59–64.

53.

Haider

and Ashraf

. 2010. Preconditioning and stem cell survival. J Cardiovasc Transl Res, 3, 89–102.

54.

Wang

Miao

Wang

Zhao

and Wang

. 2009. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell, 137, 1100–11.

55.

Herrmann

Wang

Abarbanell

Weil

Tan

and Meldrum

. 2010. Preconditioning mesenchymal stem cells with transforming growth factor-a improves mesenchymal stem cell-mediated cardioprotection. Shock, 33, 24–30.

56.

Hess

and Borlongan

. 2008. Cell-based therapy in ischemic stroke. Expert Rev Neurother, 8, 1193–201.

57.

Hicks

Lappalainen

Narkilahti

Suuronen

Corbett

Sivenius

Hovatta

and Jolkkonen

. 2009. Transplantation of human embryonic stem cell-derived neural precursor cells and enriched environment after cortical stroke in rats: cell survival and functional recovery. Eur J Neurosci, 29, 562–74.

58.

Hoke

Salloum

Kass

Das

and Kukreja

. 2012. Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. Stem Cells, 30, 326–35.

59.

Homma

Jin

Wang

Min

Yanasak

and Mivechi

. 2007. Demyelination, astrogliosis, and accumulation of ubiquitinated proteins, hallmarks of CNS disease in hsf1-deficient mice. J Neurosci, 27, 7974–86.

60.

Horie

Pereira

Niizuma

Sun

Keren-Gill

Encarnacion

Shamloo

Hamilton

Jiang

Huhn

Palmer

Bliss

and Steinberg

. 2011. Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair. Stem Cells, 29, 274–85.

61.

Jagasia

Song

Gage

and Lie

. 2006. New regulators in adult neurogenesis and their potential role for repair. Trends Mol Med, 12, 400–5.

62.

Jin

and El-Deiry

2005. Overview of cell death signaling pathways. Cancer Biol Ther, 4, 139–63.

63.

Jonas

Lin

and Tortella

. 2001. Neuroprotection from glutamate toxicity with ultra-low dose glutamate. Neuroreport, 12, 335–9.

64.

Juhasova

Mentel

Bhatia-Kissova

Zeman

Kolarov

Forte

and Polcic

. 2011. BH3-only protein Bim inhibits activity of antiapoptotic members of Bcl-2 family when expressed in yeast. FEBS Lett, 585, 2709–13.

65.

Juhaszova

Zorov

Kim

Pepe

Fishbein

Ziman

Wang

Ytrehus

Antos

Olson

and Sollott

. 2004. Glycogen synthase kinase-3b mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest, 113, 1535–49.

66.

Kamota

Morikage

Murakami

Ohshima

Kubo

Kobayashi

Mikamo

Ikeda

Matsuzaki

and Hamano

. 2009. Ischemic pre-conditioning enhances the mobilization and recruitment of bone marrow stem cells to protect against ischemia/reperfusion injury in the late phase. J Am Coll Cardiol, 53, 1814–22.

67.

Kelly

Bliss

Shah

Sun

Foo

Masel

Yenari

Weissman

Uchida

Palmer

and Steinberg

. 2004. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci U S A, 101, 11839–44.

68.

Kendig

and Belcher

. 2010. Defining hormesis: evaluation of a complex concentration response phenomenon. Int J Toxicol, 29, 235–46.

69.

Kraft

Deocaris

and Rattan

. 2006. Proteasomal oscillation during mild heat shock in aging human skin fibroblasts. Ann N Y Acad Sci, 1067, 224–7.

70.

Kramer

Erdal

Mertens

Nap

Mauermann

Steiner

Marberger

Biven

Shoshan

and Linder

. 2004. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res, 64, 1751–6.

71.

Kroemer

Galluzzi

and Brenner

. 2007. Mitochondrial membrane permeabilization in cell death. Physiol Rev, 87, 99–163.

72.

Kroemer

Galluzzi

Vandenabeele

Abrams

Alnemri

Baehrecke

Blagosklonny

El-Deiry

Golstein

Green

Hengartner

Knight

Kumar

Lipton

Malorni

Nunez

Peter

Tschopp

Yuan

Piacentini

Zhivotovsky

and Melino

. 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ, 16, 3–11.

73.

Krysko

Berghe

T Vanden

D'Herde

and Vandenabeele

. 2008a. Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods, 44, 205–21.

74.

Krysko

Berghe

T Vanden

Parthoens

D'Herde

and Vandenabeele

. 2008b. Methods for distinguishing apoptotic from necrotic cells and measuring their clearance. Methods Enzymol, 442, 307–41.

75.

Kummar

Gutierrez

Gardner

Chen

Figg

Zajac-Kaye

Chen

Steinberg

Muir

Yancey

Horneffer

Juwara

Melillo

Ivy

Merino

Neckers

Steeg

Conley

Giaccone

Doroshow

and Murgo

. 2010. Phase I trial of 17-dimethy-laminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer, 46, 340–7.

76.

Kwon

Kim

Yang

Kim

Lee

and Yoon

. 2008. Geldanamycin protects rat brain through overexpression of HSP70 and reducing brain edema after cerebral focal ischemia. Neurol Res, 30, 740–5.

77.

Lanzillotta

Sarnico

Ingrassia

Boroni

Branca

Benarese

Faraco

Blasi

Chiarugi

Spano

and Pizzi

. 2010. The acetylation of RelA in Lys310 dictates the NF-kappaB-dependent response in post-ischemic injury. Cell Death Dis, 1, e96.

78.

Lau

and Tymianski

. 2010. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch, 460, 525–42.

79.

Lee

Lin

Chang

Schultz

Heath

Hsu

Kuo

Hong

Chiang

Gong

Sze

and Chang

. 2010. TGF-b induces TIAF1 self-aggregation via type II receptor-independent signaling that leads to generation of amyloid b plaques in Alzheimer's disease. Cell Death Dis, 1, e110.

80.

Lei

Zhang

Pan

Wang

Yang

and Song

. 2010. Histone deacetylase 1 and 2 differentially regulate apoptosis by opposing effects on extracellular signal-regulated kinase 1/2. Cell Death Dis, 1, e44.

81.

Christophersen

Hall

Soulet

and Brundin

2008a. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci, 31, 146–53.

82.

Ogle

Ding

and Wei

2008b. Enhanced neurogenesis and cell migration following focal ischemia and peripheral stimulation in mice. Dev Neurobiol, 68, 1474–86.

83.

Lian

and Tse

2010. Ischaemic preconditioning and stem cell mobilisation. Thromb Haemost, 104, 194–5.

84.

Liu

Wan

Auyeung

and Mattson

. 2002. Activation of mitochondrial ATP-dependent potassium channels protects neurons against ischemia-induced death by a mechanism involving suppression of Bax translocation and cytochrome c release. J Cereb Blood Flow Metab, 22, 431–43.

85.

Liu

Zhang

Gregg

Morris

Wang

and Chopp

. 2007. Stroke induces gene profile changes associated with neurogenesis and angiogenesis in adult subventricular zone progenitor cells. J Cereb Blood Flow Metab, 27, 564–74.

86.

Lockshin

and Zakeri

. 2004. Apoptosis, autophagy, and more. Int J Biochem Cell Biol, 36, 240519.

87.

Madeo

Tavernarakis

and Kroemer

. 2010. Can autophagy promote longevity? Nat Cell Biol, 12, 842–6.

88.

Madhavan

Ourednik

and Ourednik

. 2006. Increased “vigilance” of antioxidant mechanisms in neural stem cells potentiates their capability to resist oxidative stress. Stem Cells, 24, 2110–9.

89.

Mailleux

Overholtzer

Schmelzle

Bouillet

Strasser

and Brugge

. 2007. BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms. Dev Cell, 12, 221–34.

90.

Marini

and Novelli

. 1991. DL-threo-3-hydroxyaspartate reduces NMDA receptor activation by glutamate in cultured neurons. Eur J Pharmacol, 194, 131–2.

91.

Marini

Jiang

Pan

and Lipsky

. 2008. Hormesis: a promising strategy to sustain endogenous neuronal survival pathways against neurodegenerative disorders. Ageing Res Rev, 7, 21–33.

92.

Martins

Galluzzi

and Kroemer

. 2011. Hormesis, cell death and aging. Aging (Albany NY), 3, 821–8.

93.

Mattson

2008. Hormesis defined. Ageing Res Rev, 7, 1–7.

94.

Misumi

Kim

Jung

Masuda

Urakawa

Isobe

Furuyama

Nishino

and Hida

. 2008. Enhanced neurogenesis from neural progenitor cells with G1/S-phase cell cycle arrest is mediated by transforming growth factor beta 1. Eur J Neurosci, 28, 1049–59.

95.

Mitchell

Fillinger

Sittadjody

Avila

Burd

and Limesand

. 2010. IGF1 activates cell cycle arrest following irradiation by reducing binding of DeltaNp63 to the p21 promoter. Cell Death Dis, 1, e50.

96.

Nicotera

and Melino

. 2004. Regulation of the apoptosis-necrosis switch. Oncogene, 23, 2757–65.

97.

Norgaard

Kassem

and Rattan

. 2006. Heat shock-induced enhancement of osteoblastic differentiation of hTERT-immortalized mesenchymal stem cells. Ann N Y Acad Sci, 1067, 443–7.

98.

Otani

. 2004. Reactive oxygen species as mediators of signal transduction in ischemic preconditioning. Antioxid Redox Signal, 6, 449–69.

99.

Paoletti

Maffei

Madaro

Notte

Stanganello

Cifelli

Carullo

Molinaro

Lembo

and Bouche

. 2010. Protein kinase Ctheta is required for cardiomyocyte survival and cardiac remodeling. Cell Death Dis, 1, e45.

100.

Patterson

Spahr

Daugas

Susin

Irinopoulou

Koehler

and Kroemer

. 2000. Mass spectrometric identification of proteins released from mitochondria undergoing permeability transition. Cell Death Differ, 7, 137–44.

101.

Brannen

Kim

and Sugaya

. 2001. Human neural stem cells improve cognitive function of aged brain. Neuroreport, 12, 1127–32.

102.

Rattan

. 2004. Mechanisms of hormesis through mild heat stress on human cells. Ann N Y Acad Sci, 1019, 554–8.

103.

Roitberg

Mangubat

Chen

Sugaya

Thulborn

Kordower

Pawar

Konecny

and Emborg

. 2006. Survival and early differentiation of human neural stem cells transplanted in a nonhuman primate model of stroke. J Neurosurg, 105, 96–102.

104.

Rufini

and Melino

. 2011. Cell death pathology: the war against cancer. Biochem Biophys Res Commun, 414, 445–50.

105.

Sakata

Niizuma

Yoshioka

Kim

Jung

Katsu

Narasimhan

Maier

Nishiyama

and Chan

. 2012. Minocycline-preconditioned neural stem cells enhance neuroprotection after ischemic stroke in rats. J Neurosci, 32, 3462–73.

106.

Salloum

Das

Samidurai

Hoke

Chau

Ockaili

Stasch

and Kukreja

. 2012. Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. Am J Physiol Heart Circ Physiol, 302, H1347–54.

107.

Sancho-Pelluz

Alavi

Sahaboglu

Kustermann

Farinelli

Azadi

van Veen

Romero

Paquet-Durand

and Ekstrom

. 2010. Excessive HDAC activation is critical for neurodegeneration in the rd1 mouse. Cell Death Dis, 1, e24.

108.

Savitz

Chopp

Deans

Carmichael

Phinney

and Wechsler

. 2011. Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II. Stroke, 42, 825–9.

109.

Scaffidi

Misteli

and Bianchi

. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 418, 191–5.

110.

Sivananthan

Lee

Goodyer

and LeBlanc

. 2010. Familial amyloid precursor protein mutants cause caspase-6-dependent but amyloid b-peptide-independent neuronal degeneration in primary human neuron cultures. Cell Death Dis, 1, e100.

111.

Sugaya

. 2005. Possible use of autologous stem cell therapies for Alzheimer's disease. Curr Alzheimer Res, 2, 367–76.

112.

Sugaya

Alvarez

Marutle

Kwak

and Choumkina

. 2006. Stem cell strategies for Alzheimer's disease therapy. Panminerva Med, 48, 87–96.

113.

Syntichaki

and Tavernarakis

. 2002. Death by necrosis. Uncontrollable catastrophe, or is there order behind the chaos? EMBO Rep, 3, 604–9.

114.

Tadokoro

Takahama

Shimizu

Hayashi

Endo

and Sawasaki

. 2010. Characterization of a caspase-3-substrate kinome using an N- and C-terminally tagged protein kinase library produced by a cell-free system. Cell Death Dis, 1, e89.

115.

Tenedini

Roncaglia

Ferrari

Orlandi

Bianchi

Bicciato

Tagliafico

and Ferrari

. 2010. Integrated analysis of microRNA and mRNA expression profiles in physiological myelopoiesis: role of hsa-mir-299-5p in CD34+ progenitor cells commitment. Cell Death Dis, 1, e28.

116.

Terasawa

Minami

and Minami

. 2005. Constantly updated knowledge of Hsp90. J Biochem (Tokyo), 137, 443–7.

117.

Theus

Wei

Cui

Francis

Keogh

and Yu

. 2008. In vitro hypoxic preconditioning of embryonic stem cells as a strategy of promoting cell survival and functional benefits after transplantation into the ischemic rat brain. Exp Neurol, 210, 656–70.

118.

Toma

Pittenger

Cahill

Byrne

and Kessler

. 2002. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation, 105, 93–8.

119.

Trepel

Mollapour

Giaccone

and Neckers

. 2010. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer, 10, 537–49.

120.

Vandenabeele

Galluzzi

Berghe

T Vanden

and Kroemer

. 2010. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol, 11, 700–14.

121.

Vanlangenakker

Berghe

T Vanden

and Vandenabeele

. 2012. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ, 19, 75–86.

122.

Wabnitz

Goursot

Jahraus

Kirchgessner

Hellwig

Klemke

Konstandin

and Samstag

. 2010. Mitochondrial translocation of oxidized cofilin induces caspase-independent necrotic-like programmed cell death of T cells. Cell Death Dis, 1, e58.

123.

Wang

Huang

Dai

Lee

Lin

and Mivechi

. 2001. Suppression of heat shock transcription factor HSF1 in zebrafish causes heat-induced apoptosis. Genesis, 30, 195–7.

124.

Wang

Krishnamurthy

and Tangpisuthipongsa

. 2011. Protection of murine neural progenitor cells by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin in the low nanomolar concentration range. J Neurochem, 117, 703–11.

125.

Wang

Ying

Jin

Zhang

Phillips

Moskophidis

and Mivechi

2004. Essential requirement for both hsf1 and hsf2 transcriptional activity in spermatogenesis and male fertility. Genesis, 38, 66–80.

126.

Wang

Zhang

Moskophidis

and Mivechi

. 2003. Targeted disruption of the heat shock transcription factor (hsf)-2 gene results in increased embryonic lethality, neuronal defects, and reduced spermatogenesis. Genesis, 36, 48–61.

127.

Wang

Zhao

Huang

Wang

Qian

Kranias

Wang

and Fan

. 2009. Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells, 27, 3021–31.

128.

Wang

Tao

and Jiang

. 2012. Apelin supports primary rat retinal Muller cells under chemical hypoxia and glucose deprivation. Peptides, 33, 298–306.

129.

Waza

Adachi

Katsuno

Minamiyama

Sang

Tanaka

Inukai

Doyu

and Sobue

. 2005. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med, 11, 1088–95.

130.

Waza

Adachi

Katsuno

Minamiyama

Tanaka

Doyu

and Sobue

. 2006. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J Mol Med, 84, 635–46.

131.

Wei

Fraser

and Yu

. 2012. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis, 46, 635–45.

132.

Whitesell

and Lindquist

. 2005. HSP90 and the chaperoning of cancer. Nat Rev Cancer, 5, 76172.

133.

Wiltrout

Lang

Yan

Dempsey

and Vemuganti

2007. Repairing brain after stroke: a review on post-ischemic neurogenesis. Neurochem Int, 50, 1028–41.

134.

Winkler

. 2001. Human neural stem cells improve cognitive function of aged brain. Neuroreport, 12, A33.

135.

Wisel

Khan

Kuppusamy

Mohan

Chacko

Rivera

Sun

Hideg

and Kuppusamy

. 2009. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther, 329, 543–50.

136.

Yelamanchili

Chaudhuri

Chen

Xiong

and Fox

. 2010. MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease. Cell Death Dis, 1, e77.

137.

Yuan

. 2006. Divergence from a dedicated cellular suicide mechanism: exploring the evolution of cell death. Mol Cell, 23, 1–12.

138.

Zeng

Taylor

Ogle

and Wei

. 2012. Protective effect of apelin on cultured rat bone marrow mesenchymal stem cells against apoptosis. Stem Cell Res, 8, 357–67.

139.

Zeng

Zhang

and Wei

. 2010. Neuroprotective effect of the endogenous neural peptide apelin in cultured mouse cortical neurons. Exp Cell Res, 316, 1773–83.

140.

Zhang

Shao

Lin

Zhang

Lin

Dong

and Han

. 2009. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science, 325, 332–6.

Hormesis,Cell Death,and Regenerative Medicine for Neurodegenerative Diseases

Abstract

Keywords

INTRODUCTION

CELL DEATH PATHWAYS

Apoptosis - the programmed cell death

Autophagy - A physiological hormesis case

Necrosis -

MECHANISMS OF HORMESIS IN NEURAL CELLS

STEM CELL THERAPY OF NEURODEGENERATIVE DISEASES AND STROKE

HORMESIS FOR REGENERATIVE MEDICINE

CONCLUSIONS AND PERSPECTIVES

Footnotes

ACKNOWLEDGEMENT

References